1 |
ADA
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, Primary immunodeficiency | D11017
D11017
|
Elapegademase
| 1件: 65 65 |
2 |
ADH1A
| 9件: Glycolysis / Gluconeogenesis Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease | D00707
D00707
|
Fomepizole
| 1件: 301 301 |
3 |
ADH1B
| 9件: Glycolysis / Gluconeogenesis Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease | D00707
D00707
|
Fomepizole
| 1件: 301 301 |
4 |
ADH1C
| 9件: Glycolysis / Gluconeogenesis Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease | D00707
D00707
|
Fomepizole
| 1件: 301 301 |
5 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
6 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00227
D00227
|
Aminophylline
| 1件: 63 63 |
7 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00371
D00371
|
Theophylline
| 2件: 236 236, 299 |
8 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
9 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
10 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01712
D01712
|
Theophylline
| 2件: 236 236, 299 |
11 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D02017
D02017
|
Theophylline
| 2件: 236 236, 299 |
12 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D02769
D02769
|
Adenosine phosphate
| 1件: 46 46 |
13 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D05429
D05429
|
Aminophylline
| 1件: 63 63 |
14 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D06103
D06103
|
Theophylline
| 2件: 236 236, 299 |
15 |
ADORA1
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D06104
D06104
|
Theophylline
| 2件: 236 236, 299 |
16 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
17 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D00528
D00528
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
18 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D01453
D01453
|
Caffeine
| 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
19 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D02017
D02017
|
Theophylline
| 2件: 236 236, 299 |
20 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D02769
D02769
|
Adenosine phosphate
| 1件: 46 46 |
21 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D04641
D04641
|
Istradefylline
| 1件: 6 6 |
22 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D05711
D05711
|
Regadenoson
| 1件: 58 58 |
23 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D09717
D09717
|
Preladenant
| 1件: 6 6 |
24 |
ADORA2A
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D10174
D10174
|
Tozadenant
| 1件: 6 6 |
25 |
ADORA2B
| 5件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
26 |
ADORA2B
| 5件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism | D00227
D00227
|
Aminophylline
| 1件: 63 63 |
27 |
ADORA2B
| 5件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism | D00371
D00371
|
Theophylline
| 2件: 236 236, 299 |
28 |
ADORA2B
| 5件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism | D01712
D01712
|
Theophylline
| 2件: 236 236, 299 |
29 |
ADORA2B
| 5件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism | D02769
D02769
|
Adenosine phosphate
| 1件: 46 46 |
30 |
ADORA2B
| 5件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism | D05429
D05429
|
Aminophylline
| 1件: 63 63 |
31 |
ADORA2B
| 5件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism | D06103
D06103
|
Theophylline
| 2件: 236 236, 299 |
32 |
ADORA2B
| 5件: Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism | D06104
D06104
|
Theophylline
| 2件: 236 236, 299 |
33 |
ADORA3
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
34 |
ADORA3
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D02769
D02769
|
Adenosine phosphate
| 1件: 46 46 |
35 |
ADORA3
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10971
D10971
|
Piclidenoson
| 1件: 46 46 |
36 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00076
D00076
|
Norepinephrine
| 1件: 22 22 |
37 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
38 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
39 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
40 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00454
D00454
|
Olanzapine
| 2件: 2 2, 8 |
41 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00485
D00485
|
Pseudoephedrine
| 1件: 17 17 |
42 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00511
D00511
|
Phenylephrine
| 1件: 22 22 |
43 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00608
D00608
|
Doxazosin
| 2件: 57 57, 67 |
44 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00610
D00610
|
Terazosin
| 1件: 6 6 |
45 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00636
D00636
|
Amiodarone
| 2件: 28 28, 127 |
46 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00680
D00680
|
Methylergometrine
| 3件: 118 118, 280, 288 |
47 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00996
D00996
|
Epinephrine
| 3件: 46 46, 70, 96 |
48 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
49 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01307
D01307
|
Midodrine
| 3件: 6 6, 17, 58 |
50 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02149
D02149
|
Epinephrine
| 3件: 46 46, 70, 96 |
51 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
52 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
53 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
54 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
55 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D05206
D05206
|
Norepinephrine
| 1件: 22 22 |
56 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D05648
D05648
|
Pseudoephedrine
| 1件: 17 17 |
57 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D05649
D05649
|
Pseudoephedrine
| 1件: 17 17 |
58 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D06623
D06623
|
Olanzapine
| 2件: 2 2, 8 |
59 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D07874
D07874
|
Doxazosin
| 2件: 57 57, 67 |
60 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08064
D08064
|
Ifenprodil
| 1件: 85 85 |
61 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08207
D08207
|
Methylergometrine
| 3件: 118 118, 280, 288 |
62 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08220
D08220
|
Midodrine
| 3件: 6 6, 17, 58 |
63 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08365
D08365
|
Phenylephrine
| 1件: 22 22 |
64 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
65 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08569
D08569
|
Terazosin
| 1件: 6 6 |
66 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00076
D00076
|
Norepinephrine
| 1件: 22 22 |
67 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
68 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
69 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
70 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00454
D00454
|
Olanzapine
| 2件: 2 2, 8 |
71 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00485
D00485
|
Pseudoephedrine
| 1件: 17 17 |
72 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00511
D00511
|
Phenylephrine
| 1件: 22 22 |
73 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00608
D00608
|
Doxazosin
| 2件: 57 57, 67 |
74 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00610
D00610
|
Terazosin
| 1件: 6 6 |
75 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00636
D00636
|
Amiodarone
| 2件: 28 28, 127 |
76 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00680
D00680
|
Methylergometrine
| 3件: 118 118, 280, 288 |
77 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00996
D00996
|
Epinephrine
| 3件: 46 46, 70, 96 |
78 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
79 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01307
D01307
|
Midodrine
| 3件: 6 6, 17, 58 |
80 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02149
D02149
|
Epinephrine
| 3件: 46 46, 70, 96 |
81 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
82 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
83 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
84 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
85 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D05206
D05206
|
Norepinephrine
| 1件: 22 22 |
86 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D05648
D05648
|
Pseudoephedrine
| 1件: 17 17 |
87 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D05649
D05649
|
Pseudoephedrine
| 1件: 17 17 |
88 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D06623
D06623
|
Olanzapine
| 2件: 2 2, 8 |
89 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D07874
D07874
|
Doxazosin
| 2件: 57 57, 67 |
90 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08064
D08064
|
Ifenprodil
| 1件: 85 85 |
91 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08207
D08207
|
Methylergometrine
| 3件: 118 118, 280, 288 |
92 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08220
D08220
|
Midodrine
| 3件: 6 6, 17, 58 |
93 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08365
D08365
|
Phenylephrine
| 1件: 22 22 |
94 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
95 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08569
D08569
|
Terazosin
| 1件: 6 6 |
96 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00076
D00076
|
Norepinephrine
| 1件: 22 22 |
97 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
98 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
99 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
100 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00454
D00454
|
Olanzapine
| 2件: 2 2, 8 |
101 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00485
D00485
|
Pseudoephedrine
| 1件: 17 17 |
102 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00511
D00511
|
Phenylephrine
| 1件: 22 22 |
103 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00608
D00608
|
Doxazosin
| 2件: 57 57, 67 |
104 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00610
D00610
|
Terazosin
| 1件: 6 6 |
105 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00636
D00636
|
Amiodarone
| 2件: 28 28, 127 |
106 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00680
D00680
|
Methylergometrine
| 3件: 118 118, 280, 288 |
107 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00996
D00996
|
Epinephrine
| 3件: 46 46, 70, 96 |
108 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
109 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01307
D01307
|
Midodrine
| 3件: 6 6, 17, 58 |
110 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01692
D01692
|
Alfuzosin
| 1件: 13 13 |
111 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01965
D01965
|
Silodosin
| 2件: 6 6, 13 |
112 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02149
D02149
|
Epinephrine
| 3件: 46 46, 70, 96 |
113 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
114 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
115 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
116 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
117 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D05206
D05206
|
Norepinephrine
| 1件: 22 22 |
118 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D05648
D05648
|
Pseudoephedrine
| 1件: 17 17 |
119 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D05649
D05649
|
Pseudoephedrine
| 1件: 17 17 |
120 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D06623
D06623
|
Olanzapine
| 2件: 2 2, 8 |
121 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D07124
D07124
|
Alfuzosin
| 1件: 13 13 |
122 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D07874
D07874
|
Doxazosin
| 2件: 57 57, 67 |
123 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08064
D08064
|
Ifenprodil
| 1件: 85 85 |
124 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08207
D08207
|
Methylergometrine
| 3件: 118 118, 280, 288 |
125 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08220
D08220
|
Midodrine
| 3件: 6 6, 17, 58 |
126 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08365
D08365
|
Phenylephrine
| 1件: 22 22 |
127 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
128 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D08569
D08569
|
Terazosin
| 1件: 6 6 |
129 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00076
D00076
|
Norepinephrine
| 1件: 22 22 |
130 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
131 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
132 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00270
D00270
|
Chlorpromazine
| 1件: 254 254 |
133 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
134 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
135 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00405
D00405
|
Methyldopa
| 1件: 323 323 |
136 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00485
D00485
|
Pseudoephedrine
| 1件: 17 17 |
137 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
138 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00560
D00560
|
Pimozide
| 1件: 2 2 |
139 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00604
D00604
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
140 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00606
D00606
|
Guanfacine
| 1件: 193 193 |
141 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00680
D00680
|
Methylergometrine
| 3件: 118 118, 280, 288 |
142 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00776
D00776
|
Tizanidine
| 1件: 13 13 |
143 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00789
D00789
|
Chlorpromazine
| 1件: 254 254 |
144 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00996
D00996
|
Epinephrine
| 3件: 46 46, 70, 96 |
145 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01008
D01008
|
Apraclonidine
| 1件: 11 11 |
146 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01205
D01205
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
147 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
148 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02076
D02076
|
Brimonidine
| 2件: 13 13, 90 |
149 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02149
D02149
|
Epinephrine
| 3件: 46 46, 70, 96 |
150 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
151 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
152 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D03274
D03274
|
Chlorpromazine
| 1件: 254 254 |
153 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04034
D04034
|
Chlorpromazine
| 1件: 254 254 |
154 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04375
D04375
|
Guanabenz
| 2件: 2 2, 13 |
155 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D05206
D05206
|
Norepinephrine
| 1件: 22 22 |
156 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D05648
D05648
|
Pseudoephedrine
| 1件: 17 17 |
157 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D05649
D05649
|
Pseudoephedrine
| 1件: 17 17 |
158 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07461
D07461
|
Apraclonidine
| 1件: 11 11 |
159 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07540
D07540
|
Brimonidine
| 2件: 13 13, 90 |
160 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08031
D08031
|
Guanfacine
| 1件: 193 193 |
161 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08205
D08205
|
Methyldopa
| 1件: 323 323 |
162 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08207
D08207
|
Methylergometrine
| 3件: 118 118, 280, 288 |
163 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
164 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08482
D08482
|
Rilmenidine
| 1件: 8 8 |
165 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08611
D08611
|
Tizanidine
| 1件: 13 13 |
166 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08685
D08685
|
Yohimbine
| 1件: 6 6 |
167 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00076
D00076
|
Norepinephrine
| 1件: 22 22 |
168 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
169 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
170 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00270
D00270
|
Chlorpromazine
| 1件: 254 254 |
171 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
172 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
173 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00405
D00405
|
Methyldopa
| 1件: 323 323 |
174 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00485
D00485
|
Pseudoephedrine
| 1件: 17 17 |
175 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
176 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00604
D00604
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
177 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00680
D00680
|
Methylergometrine
| 3件: 118 118, 280, 288 |
178 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00776
D00776
|
Tizanidine
| 1件: 13 13 |
179 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00789
D00789
|
Chlorpromazine
| 1件: 254 254 |
180 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00996
D00996
|
Epinephrine
| 3件: 46 46, 70, 96 |
181 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01008
D01008
|
Apraclonidine
| 1件: 11 11 |
182 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01205
D01205
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
183 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
184 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02076
D02076
|
Brimonidine
| 2件: 13 13, 90 |
185 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02149
D02149
|
Epinephrine
| 3件: 46 46, 70, 96 |
186 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
187 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
188 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D03274
D03274
|
Chlorpromazine
| 1件: 254 254 |
189 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04034
D04034
|
Chlorpromazine
| 1件: 254 254 |
190 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04375
D04375
|
Guanabenz
| 2件: 2 2, 13 |
191 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D05206
D05206
|
Norepinephrine
| 1件: 22 22 |
192 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D05648
D05648
|
Pseudoephedrine
| 1件: 17 17 |
193 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D05649
D05649
|
Pseudoephedrine
| 1件: 17 17 |
194 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07461
D07461
|
Apraclonidine
| 1件: 11 11 |
195 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07540
D07540
|
Brimonidine
| 2件: 13 13, 90 |
196 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08205
D08205
|
Methyldopa
| 1件: 323 323 |
197 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08207
D08207
|
Methylergometrine
| 3件: 118 118, 280, 288 |
198 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
199 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08482
D08482
|
Rilmenidine
| 1件: 8 8 |
200 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08611
D08611
|
Tizanidine
| 1件: 13 13 |
201 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08685
D08685
|
Yohimbine
| 1件: 6 6 |
202 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00076
D00076
|
Norepinephrine
| 1件: 22 22 |
203 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
204 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
205 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00270
D00270
|
Chlorpromazine
| 1件: 254 254 |
206 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
207 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
208 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00405
D00405
|
Methyldopa
| 1件: 323 323 |
209 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00485
D00485
|
Pseudoephedrine
| 1件: 17 17 |
210 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
211 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00604
D00604
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
212 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00680
D00680
|
Methylergometrine
| 3件: 118 118, 280, 288 |
213 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00776
D00776
|
Tizanidine
| 1件: 13 13 |
214 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00789
D00789
|
Chlorpromazine
| 1件: 254 254 |
215 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00996
D00996
|
Epinephrine
| 3件: 46 46, 70, 96 |
216 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01008
D01008
|
Apraclonidine
| 1件: 11 11 |
217 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01205
D01205
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
218 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
219 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02076
D02076
|
Brimonidine
| 2件: 13 13, 90 |
220 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02149
D02149
|
Epinephrine
| 3件: 46 46, 70, 96 |
221 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02268
D02268
|
Ergoloid mesylate
| 2件: 6 6, 206 |
222 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
223 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D03274
D03274
|
Chlorpromazine
| 1件: 254 254 |
224 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04034
D04034
|
Chlorpromazine
| 1件: 254 254 |
225 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04375
D04375
|
Guanabenz
| 2件: 2 2, 13 |
226 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D05206
D05206
|
Norepinephrine
| 1件: 22 22 |
227 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D05648
D05648
|
Pseudoephedrine
| 1件: 17 17 |
228 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D05649
D05649
|
Pseudoephedrine
| 1件: 17 17 |
229 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07461
D07461
|
Apraclonidine
| 1件: 11 11 |
230 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07540
D07540
|
Brimonidine
| 2件: 13 13, 90 |
231 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08205
D08205
|
Methyldopa
| 1件: 323 323 |
232 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08207
D08207
|
Methylergometrine
| 3件: 118 118, 280, 288 |
233 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
234 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08482
D08482
|
Rilmenidine
| 1件: 8 8 |
235 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08611
D08611
|
Tizanidine
| 1件: 13 13 |
236 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08685
D08685
|
Yohimbine
| 1件: 6 6 |
237 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00076
D00076
|
Norepinephrine
| 1件: 22 22 |
238 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
239 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
240 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00235
D00235
|
Atenolol
| 1件: 167 167 |
241 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
242 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00378
D00378
|
Timolol
| 2件: 157 157, 227 |
243 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00432
D00432
|
Nadolol
| 1件: 6 6 |
244 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00483
D00483
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
245 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00485
D00485
|
Pseudoephedrine
| 1件: 17 17 |
246 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00601
D00601
|
Metoprolol
| 6件: 17 17, 57, 58, 113, 193, 226 |
247 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00603
D00603
|
Timolol
| 2件: 157 157, 227 |
248 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00632
D00632
|
Dobutamine
| 3件: 57 57, 58, 215 |
249 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00634
D00634
|
Bisoprolol
| 3件: 67 67, 86, 113 |
250 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00636
D00636
|
Amiodarone
| 2件: 28 28, 127 |
251 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00644
D00644
|
Esmolol
| 1件: 58 58 |
252 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00996
D00996
|
Epinephrine
| 3件: 46 46, 70, 96 |
253 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
254 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02149
D02149
|
Epinephrine
| 3件: 46 46, 70, 96 |
255 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02342
D02342
|
Bisoprolol
| 3件: 67 67, 86, 113 |
256 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
257 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02358
D02358
|
Metoprolol
| 6件: 17 17, 57, 58, 113, 193, 226 |
258 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
259 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
260 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D03879
D03879
|
Dobutamine
| 3件: 57 57, 58, 215 |
261 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D03880
D03880
|
Dobutamine
| 3件: 57 57, 58, 215 |
262 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D03881
D03881
|
Dobutamine
| 3件: 57 57, 58, 215 |
263 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D05011
D05011
|
Metoprolol
| 6件: 17 17, 57, 58, 113, 193, 226 |
264 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D05127
D05127
|
Nebivolol
| 4件: 17 17, 85, 113, 167 |
265 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D05206
D05206
|
Norepinephrine
| 1件: 22 22 |
266 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D05648
D05648
|
Pseudoephedrine
| 1件: 17 17 |
267 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D05649
D05649
|
Pseudoephedrine
| 1件: 17 17 |
268 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D07660
D07660
|
Celiprolol
| 1件: 168 168 |
269 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D07916
D07916
|
Esmolol
| 1件: 58 58 |
270 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08443
D08443
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
271 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
272 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08600
D08600
|
Timolol
| 2件: 157 157, 227 |
273 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00076
D00076
|
Norepinephrine
| 1件: 22 22 |
274 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
275 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
276 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00255
D00255
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
277 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00378
D00378
|
Timolol
| 2件: 157 157, 227 |
278 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00432
D00432
|
Nadolol
| 1件: 6 6 |
279 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00483
D00483
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
280 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00485
D00485
|
Pseudoephedrine
| 1件: 17 17 |
281 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00603
D00603
|
Timolol
| 2件: 157 157, 227 |
282 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00687
D00687
|
Salmeterol
| 1件: 299 299 |
283 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00688
D00688
|
Terbutaline
| 1件: 118 118 |
284 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00996
D00996
|
Epinephrine
| 3件: 46 46, 70, 96 |
285 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
286 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01373
D01373
|
Formoterol
| 3件: 85 85, 228, 299 |
287 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02147
D02147
|
Salbutamol
| 14件: 3 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 |
288 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02149
D02149
|
Epinephrine
| 3件: 46 46, 70, 96 |
289 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02151
D02151
|
Tulobuterol
| 1件: 6 6 |
290 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
291 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D03415
D03415
|
Carvedilol
| 5件: 6 6, 57, 86, 113, 210 |
292 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05206
D05206
|
Norepinephrine
| 1件: 22 22 |
293 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05277
D05277
|
Formoterol
| 3件: 85 85, 228, 299 |
294 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05648
D05648
|
Pseudoephedrine
| 1件: 17 17 |
295 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05649
D05649
|
Pseudoephedrine
| 1件: 17 17 |
296 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05792
D05792
|
Salmeterol
| 1件: 299 299 |
297 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D07713
D07713
|
Clenbuterol
| 5件: 1 1, 2, 6, 13, 256 |
298 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D07990
D07990
|
Formoterol
| 3件: 85 85, 228, 299 |
299 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08092
D08092
|
Isoxsuprine
| 1件: 13 13 |
300 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08124
D08124
|
Levosalbutamol
| 1件: 49 49 |
301 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
302 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
303 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08570
D08570
|
Terbutaline
| 1件: 118 118 |
304 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08600
D08600
|
Timolol
| 2件: 157 157, 227 |
305 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00076
D00076
|
Norepinephrine
| 1件: 22 22 |
306 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
307 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
308 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00483
D00483
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
309 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00485
D00485
|
Pseudoephedrine
| 1件: 17 17 |
310 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00996
D00996
|
Epinephrine
| 3件: 46 46, 70, 96 |
311 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
312 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02149
D02149
|
Epinephrine
| 3件: 46 46, 70, 96 |
313 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
314 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05206
D05206
|
Norepinephrine
| 1件: 22 22 |
315 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05648
D05648
|
Pseudoephedrine
| 1件: 17 17 |
316 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05649
D05649
|
Pseudoephedrine
| 1件: 17 17 |
317 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 7件: 6 6, 158, 167, 215, 227, 278, 296 |
318 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
319 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D09535
D09535
|
Mirabegron
| 4件: 6 6, 13, 53, 226 |
320 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00251
D00251
|
Captopril
| 8件: 6 6, 17, 46, 86, 96, 97, 107, 271 |
321 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00362
D00362
|
Lisinopril
| 7件: 19 19, 46, 49, 66, 67, 113, 222 |
322 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00421
D00421
|
Ramipril
| 7件: 46 46, 49, 66, 67, 113, 218, 257 |
323 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00459
D00459
|
Quinapril
| 1件: 19 19 |
324 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00620
D00620
|
Benazepril
| 4件: 49 49, 57, 218, 224 |
325 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00621
D00621
|
Enalapril
| 6件: 19 19, 46, 66, 113, 210, 222 |
326 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00623
D00623
|
Moexipril
| 1件: 93 93 |
327 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00624
D00624
|
Perindopril
| 4件: 58 58, 113, 167, 222 |
328 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D01069
D01069
|
Cilazapril
| 1件: 66 66 |
329 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D03752
D03752
|
Quinapril
| 1件: 19 19 |
330 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D03753
D03753
|
Perindopril
| 4件: 58 58, 113, 167, 222 |
331 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D07499
D07499
|
Benazepril
| 4件: 49 49, 57, 218, 224 |
332 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D07699
D07699
|
Cilazapril
| 1件: 66 66 |
333 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D07892
D07892
|
Enalapril
| 6件: 19 19, 46, 66, 113, 210, 222 |
334 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D08068
D08068
|
Imidapril
| 1件: 67 67 |
335 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D08131
D08131
|
Lisinopril
| 7件: 19 19, 46, 49, 66, 67, 113, 222 |
336 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D08225
D08225
|
Moexipril
| 1件: 93 93 |
337 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00150
D00150
|
Angiotensin II
| 7件: 17 17, 19, 46, 66, 86, 222, 224 |
338 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00357
D00357
|
Losartan
| 18件: 17 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
339 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00400
D00400
|
Valsartan
| 7件: 57 57, 58, 66, 75, 218, 222, 224 |
340 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00522
D00522
|
Candesartan cilexetil
| 1件: 67 67 |
341 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00522
D00522
|
Candesartan
| 2件: 58 58, 67 |
342 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00523
D00523
|
Irbesartan
| 4件: 66 66, 167, 168, 222 |
343 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00626
D00626
|
Candesartan cilexetil
| 1件: 67 67 |
344 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00627
D00627
|
Telmisartan
| 2件: 66 66, 67 |
345 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D02014
D02014
|
Angiotensin II
| 7件: 17 17, 19, 46, 66, 86, 222, 224 |
346 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D08146
D08146
|
Losartan
| 18件: 17 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
347 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D11776
D11776
|
Sparsentan
| 3件: 66 66, 218, 222 |
348 |
AGTR2
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system | D00150
D00150
|
Angiotensin II
| 7件: 17 17, 19, 46, 66, 86, 222, 224 |
349 |
AGTR2
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system | D02014
D02014
|
Angiotensin II
| 7件: 17 17, 19, 46, 66, 86, 222, 224 |
350 |
ABAT
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
351 |
ABAT
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse | D00535
D00535
|
Vigabatrin
| 2件: 145 145, 158 |
352 |
ALAS1
| 4件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Porphyrin metabolism, Metabolic pathways, Biosynthesis of cofactors | D10003
D10003
|
Hemin
| 1件: 254 254 |
353 |
ALAS1
| 4件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Porphyrin metabolism, Metabolic pathways, Biosynthesis of cofactors | D11702
D11702
|
Givosiran
| 1件: 254 254 |
354 |
ALAS2
| 4件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Porphyrin metabolism, Metabolic pathways, Biosynthesis of cofactors | D10003
D10003
|
Hemin
| 1件: 254 254 |
355 |
ABCD1
| 2件: ABC transporters ABC transporters, Peroxisome | D12150
D12150
|
Elivaldogene autotemcel
| 1件: 20 20 |
356 |
ALK
| 3件: Pathways in cancer Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09731
D09731
|
Crizotinib
| 1件: 34 34 |
357 |
ALK
| 3件: Pathways in cancer Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10866
D10866
|
Brigatinib
| 1件: 34 34 |
358 |
ALOX5
| 6件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Fc epsilon RI signaling pathway, Serotonergic synapse, Ovarian steroidogenesis, Toxoplasmosis | D00414
D00414
|
Zileuton
| 3件: 85 85, 160, 164 |
359 |
ALOX5
| 6件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Fc epsilon RI signaling pathway, Serotonergic synapse, Ovarian steroidogenesis, Toxoplasmosis | D01773
D01773
|
Oxatomide
| 1件: 113 113 |
360 |
ALPL
| 4件: Thiamine metabolism Thiamine metabolism, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors | D10595
D10595
|
Asfotase alfa
| 1件: 172 172 |
361 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D01441
D01441
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
362 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D03252
D03252
|
Bosutinib
| 2件: 2 2, 67 |
363 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D03658
D03658
|
Dasatinib
| 2件: 51 51, 85 |
364 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D06414
D06414
|
Dasatinib
| 2件: 51 51, 85 |
365 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D08066
D08066
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
366 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D08953
D08953
|
Nilotinib
| 5件: 6 6, 8, 34, 51, 86 |
367 |
ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D09664
D09664
|
Saracatinib
| 3件: 6 6, 89, 272 |
368 |
ANGPTL3
| 1件: Cholesterol metabolism Cholesterol metabolism | D11753
D11753
|
Evinacumab
| 1件: 79 79 |
369 |
AMY2A
| 5件: Starch and sucrose metabolism Starch and sucrose metabolism, Metabolic pathways, Salivary secretion, Pancreatic secretion, Carbohydrate digestion and absorption | D00216
D00216
|
Acarbose
| 1件: 298 298 |
370 |
AMY2B
| 5件: Starch and sucrose metabolism Starch and sucrose metabolism, Metabolic pathways, Salivary secretion, Pancreatic secretion, Carbohydrate digestion and absorption | D00216
D00216
|
Acarbose
| 1件: 298 298 |
371 |
ANPEP
| 4件: Glutathione metabolism Glutathione metabolism, Metabolic pathways, Renin-angiotensin system, Hematopoietic cell lineage | D00087
D00087
|
Ubenimex
| 1件: 86 86 |
372 |
APCS
| - | D11464
D11464
|
Miridesap
| 1件: 28 28 |
373 |
APCS
| - | D11471
D11471
|
Dezamizumab
| 1件: 28 28 |
374 |
APOC3
| 2件: PPAR signaling pathway PPAR signaling pathway, Cholesterol metabolism | D11648
D11648
|
Volanesorsen
| 1件: 265 265 |
375 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00075
D00075
|
Testosterone
| 9件: 1 1, 2, 3, 13, 60, 76, 78, 113, 265 |
376 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00289
D00289
|
Danazol
| 5件: 60 60, 63, 64, 65, 285 |
377 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00444
D00444
|
Stanozolol
| 1件: 60 60 |
378 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00462
D00462
|
Oxandrolone
| 2件: 211 211, 285 |
379 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00586
D00586
|
Flutamide
| 1件: 81 81 |
380 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00955
D00955
|
Nandrolone decanoate
| 2件: 60 60, 85 |
381 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00957
D00957
|
Testosterone
| 9件: 1 1, 2, 3, 13, 60, 76, 78, 113, 265 |
382 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00958
D00958
|
Testosterone
| 9件: 1 1, 2, 3, 13, 60, 76, 78, 113, 265 |
383 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00958
D00958
|
Testosterone enanthate
| 2件: 13 13, 113 |
384 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00959
D00959
|
Testosterone
| 9件: 1 1, 2, 3, 13, 60, 76, 78, 113, 265 |
385 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00959
D00959
|
Testosterone propionate
| 1件: 113 113 |
386 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D03338
D03338
|
Calusterone
| 3件: 2 2, 46, 71 |
387 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D06085
D06085
|
Testosterone
| 9件: 1 1, 2, 3, 13, 60, 76, 78, 113, 265 |
388 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D06087
D06087
|
Testosterone
| 9件: 1 1, 2, 3, 13, 60, 76, 78, 113, 265 |
389 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D06087
D06087
|
Testosterone undecanoate
| 2件: 13 13, 60 |
390 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08250
D08250
|
Nandrolone
| 2件: 60 60, 85 |
391 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08409
D08409
|
Prasterone
| 6件: 49 49, 53, 83, 86, 96, 113 |
392 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08573
D08573
|
Testosterone decanoate
| 1件: 113 113 |
393 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08574
D08574
|
Testosterone phenylpropionate
| 1件: 113 113 |
394 |
ARSB
| 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Metabolic pathways, Lysosome | D06565
D06565
|
Galsulfase
| 1件: 19 19 |
395 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D00487
D00487
|
Pyridostigmine
| 4件: 3 3, 6, 11, 256 |
396 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D00670
D00670
|
Donepezil
| 9件: 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
397 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D02068
D02068
|
Tacrine
| 3件: 46 46, 271, 299 |
398 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D02173
D02173
|
Galantamine
| 2件: 6 6, 127 |
399 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D02558
D02558
|
Rivastigmine
| 3件: 5 5, 6, 13 |
400 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D03822
D03822
|
Rivastigmine
| 3件: 5 5, 6, 13 |
401 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D04292
D04292
|
Galantamine
| 2件: 6 6, 127 |
402 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D07869
D07869
|
Donepezil
| 9件: 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
403 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D08261
D08261
|
Neostigmine
| 1件: 11 11 |
404 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D08555
D08555
|
Tacrine
| 3件: 46 46, 271, 299 |
405 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D09917
D09917
|
Latrepirdine
| 1件: 8 8 |
406 |
ATP1A1
| 18件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption | D00297
D00297
|
Digitoxin
| 1件: 299 299 |
407 |
ATP1A1
| 18件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption | D00298
D00298
|
Digoxin
| 3件: 8 8, 46, 210 |
408 |
ATP1A2
| 18件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption | D00297
D00297
|
Digitoxin
| 1件: 299 299 |
409 |
ATP1A2
| 18件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption | D00298
D00298
|
Digoxin
| 3件: 8 8, 46, 210 |
410 |
ATP1A3
| 18件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption | D00297
D00297
|
Digitoxin
| 1件: 299 299 |
411 |
ATP1A3
| 18件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption | D00298
D00298
|
Digoxin
| 3件: 8 8, 46, 210 |
412 |
ATP1A4
| 18件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption | D00297
D00297
|
Digitoxin
| 1件: 299 299 |
413 |
ATP1A4
| 18件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption | D00298
D00298
|
Digoxin
| 3件: 8 8, 46, 210 |
414 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00355
D00355
|
Lansoprazole
| 7件: 63 63, 71, 85, 98, 166, 222, 299 |
415 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
416 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00724
D00724
|
Rabeprazole
| 2件: 2 2, 51 |
417 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01207
D01207
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
418 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01984
D01984
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
419 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D02593
D02593
|
Pantoprazole
| 2件: 13 13, 65 |
420 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D04056
D04056
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
421 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05259
D05259
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
422 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05261
D05261
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
423 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05353
D05353
|
Pantoprazole
| 2件: 13 13, 65 |
424 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D07917
D07917
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
425 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D08463
D08463
|
Rabeprazole
| 2件: 2 2, 51 |
426 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D08903
D08903
|
Dexlansoprazole
| 1件: 98 98 |
427 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D09339
D09339
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
428 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D11784
D11784
|
Vonoprazan
| 2件: 63 63, 98 |
429 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00355
D00355
|
Lansoprazole
| 7件: 63 63, 71, 85, 98, 166, 222, 299 |
430 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
431 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00724
D00724
|
Rabeprazole
| 2件: 2 2, 51 |
432 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01207
D01207
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
433 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01984
D01984
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
434 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D02593
D02593
|
Pantoprazole
| 2件: 13 13, 65 |
435 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D04056
D04056
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
436 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05259
D05259
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
437 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05261
D05261
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
438 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05353
D05353
|
Pantoprazole
| 2件: 13 13, 65 |
439 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D07917
D07917
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
440 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D08463
D08463
|
Rabeprazole
| 2件: 2 2, 51 |
441 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D08903
D08903
|
Dexlansoprazole
| 1件: 98 98 |
442 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D09339
D09339
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
443 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D11784
D11784
|
Vonoprazan
| 2件: 63 63, 98 |
444 |
APH1A
| 2件: Notch signaling pathway Notch signaling pathway, Alzheimer disease | D09010
D09010
|
Tarenflurbil
| 1件: 13 13 |
445 |
AVPR1A
| 4件: Calcium signaling pathway Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction | D00101
D00101
|
Vasopressin
| 1件: 210 210 |
446 |
AVPR1A
| 4件: Calcium signaling pathway Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction | D01236
D01236
|
Conivaptan
| 1件: 86 86 |
447 |
AVPR1A
| 4件: Calcium signaling pathway Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction | D06672
D06672
|
Terlipressin
| 1件: 299 299 |
448 |
AVPR1A
| 4件: Calcium signaling pathway Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction | D07748
D07748
|
Conivaptan
| 1件: 86 86 |
449 |
AVPR1B
| 4件: Calcium signaling pathway Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction | D00101
D00101
|
Vasopressin
| 1件: 210 210 |
450 |
AVPR1B
| 4件: Calcium signaling pathway Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction | D06672
D06672
|
Terlipressin
| 1件: 299 299 |
451 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D00101
D00101
|
Vasopressin
| 1件: 210 210 |
452 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D00291
D00291
|
Desmopressin
| 6件: 6 6, 64, 72, 75, 225, 288 |
453 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D01213
D01213
|
Tolvaptan
| 3件: 67 67, 72, 225 |
454 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D01236
D01236
|
Conivaptan
| 1件: 86 86 |
455 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D02235
D02235
|
Desmopressin
| 6件: 6 6, 64, 72, 75, 225, 288 |
456 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D04752
D04752
|
Lixivaptan
| 1件: 67 67 |
457 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D06672
D06672
|
Terlipressin
| 1件: 299 299 |
458 |
AVPR2
| 3件: Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D07748
D07748
|
Conivaptan
| 1件: 86 86 |
459 |
AXL
| 1件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance | D10062
D10062
|
Cabozantinib
| 1件: 34 34 |
460 |
ABCC8
| 3件: ABC transporters ABC transporters, Insulin secretion, Type II diabetes mellitus | D00294
D00294
|
Diazoxide
| 2件: 13 13, 193 |
461 |
ABCC8
| 3件: ABC transporters ABC transporters, Insulin secretion, Type II diabetes mellitus | D00418
D00418
|
Minoxidil
| 1件: 179 179 |
462 |
ABCC8
| 3件: ABC transporters ABC transporters, Insulin secretion, Type II diabetes mellitus | D00594
D00594
|
Repaglinide
| 3件: 6 6, 21, 299 |
463 |
ADAM17
| 4件: Notch signaling pathway Notch signaling pathway, Alzheimer disease, Epithelial cell signaling in Helicobacter pylori infection, Coronavirus disease - COVID-19 | D08859
D08859
|
Apratastat
| 1件: 46 46 |
464 |
ALDH5A1
| 3件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
465 |
AOC3
| 5件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Tyrosine metabolism, Phenylalanine metabolism, beta-Alanine metabolism, Metabolic pathways | D08044
D08044
|
Hydralazine
| 1件: 67 67 |
466 |
ACVR2A
| 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis | D09670
D09670
|
Sotatercept
| 2件: 86 86, 284 |
467 |
ACVR2A
| 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis | D10620
D10620
|
Bimagrumab
| 1件: 15 15 |
468 |
ACVR2B
| 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis | D10620
D10620
|
Bimagrumab
| 1件: 15 15 |